References
- Chen XZ, Zhang WK, Yang K, et al. (2012). Correlation between serum CA724 and gastric cancer: multiple analyses based on Chinese population. Mol Biol Rep 39:9031–9
- Crane SJ, Locke GR, Harmsen WS, et al. (2008). Survival trends in patients with gastric and esophageal adenocarcinomas: a population-based study. Mayo Clin Proc 83:1087–94
- Fan B, Xiong B. (2011). Investigation of serum tumor markers in the diagnosis of gastric cancer. Hepatogastroenterology 58:239–45
- Greene FL, Sobin LH. (2009). A worldwide approach to the TNM staging system: collaborative efforts of the AJCC and UICC. J Surg Oncol 99:269–72
- Guadagni F, Roselli M, Cosimelli M, et al. (1993). Correlation between positive CA 72-4 serum levels and lymph node involvement in patients with gastric carcinoma. Anticancer Res 13:2409–13
- Haas M, Heinemann V, Kullmann F, et al. (2013). Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol 139:681–9
- Jackson C, Cunningham D, Oliveira J. (2009). Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20:34–6
- Jemal A, Bray F, Center MM, et al. (2011). Global cancer statistics. CA Cancer J Clin 61:69–90
- Lai IR, Lee WJ, Huang M, et al. (2002). Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterology 49:1157–60
- Li F, Zhang R, Liang H, et al. (2013). The pattern and risk factors of recurrence of proximal gastric cancer after curative resection. J Surg Oncol 107:130--5
- Li GC, Zhang Z, Ma XJ, et al. (2012). Are biomarkers correlated with recurrence patterns in patients with resectable gastric adenocarcinoma. Mol Biol Rep 39:399–405
- Marrelli D, Roviello F, De Stefano A, et al. (1999). Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncol-Basel 57:55–62
- Mattar R, Alves DAC, DiFavero GM, et al. (2002). Preoperative serum levels of CA 72-4, CEA, CA 19-9, and alpha-fetoprotein in patients with gastric cancer. Rev Hosp Clin Fac Med Sao Paulo 57:89–92
- Spila A, Roselli M, Cosimelli M, et al. (1996). Clinical utility of CA 72-4 serum marker in the staging and immediate post-surgical management of gastric cancer patients. Anticancer Res 16:2241–7
- Ucar E, Semerci E, Ustun H, et al. (2008). Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther 25:1075–84
- Van Cutsem E, Dicato M, Geva R, et al. (2011). The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol 22:v1–9
- Victorzon M, Haglund C, Lundin J, et al. (1995). A prognostic value of CA 19-9 but not of CEA in patients with gastric cancer. Eur J Surg Oncol 21:379–84
- Ychou M, Duffour J, Kramar A, et al. (2000). Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers 16:105–10
- Yu H, Son GM, Joh YG. (2013). The clinical significance of preoperative serum levels of carbohydrate antigen 19-9 in colorectal cancer. J Korean Surg Soc 84:231–7